KO
Kopran Ltd (KOPRAN)
₹263.16
Mkt cap
₹1,272 Cr
P/E ratio
32.40
P/B
2.41
Div yield
1.14%
ROE
4.91%
ROCE
6.65%
EPS (TTM)
₹8.12
Book value
₹109
52W range
107–296
Sector
Healthcare
Price history
Previous close
Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.
NSE KOPRANBSE 524280
Health check
Cautious
ValuationFair
ProfitabilityWeak
GrowthModerate
TechnicalsNeutral
52-week range
−11.04% from high₹263
₹107+145.94% from low₹296
Current
₹263.16
Prev close
₹267.05
Day
−1.46%
Price performance
1D
−0.99%
1W
−8.53%
1M
+1.05%
3M
+32.39%
6M
+58.09%
1Y
+85.06%
YTD
+73.04%
Financials
Revenue, profit & margin
P/E ratio
32.4×
KOPRAN is 0% below the sector median of 32.5×
KOPRAN32.4×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 152.59 | 158.92 | 186.08 | 139.44 | 151.56 | 166.24 | 172.36 | 135.22 | 117.91 | 194.28 | 234.02 | 153.99 | 211.26 | |
| YoY Sales growth | +30.45% | +0.58% | +24.99% | +19.18% | -0.68% | +4.61% | -7.37% | -3.03% | -22.20% | +16.87% | +35.77% | +13.88% | +79.17% | |
| Expenses | 129.76 | 135.34 | 164.39 | 121.28 | 136.83 | 146.39 | 155.27 | 121.09 | 123.19 | 176.52 | 201.08 | 138.18 | 195.85 | |
| Operating Profit | 22.83 | 23.58 | 21.69 | 18.16 | 14.73 | 19.85 | 17.09 | 14.13 | -5.28 | 17.76 | 32.94 | 15.81 | 15.41 | |
| OPM % | 14.96% | 14.84% | 11.66% | 13.02% | 9.72% | 11.94% | 9.92% | 10.45% | -4.48% | 9.14% | 14.08% | 10.27% | 7.29% | |
| Other Income | 0.13 | 2.43 | 9.67 | 2.63 | 1.00 | 0.17 | 3.26 | 2.56 | 0.03 | 0.07 | 0.09 | 2.05 | 0.62 | |
| Interest | 1.94 | 2.24 | 2.59 | 2.18 | 2.23 | 2.16 | 2.77 | 2.54 | 2.09 | 2.67 | 3.17 | 3.28 | 4.25 | |
| Depreciation | 2.77 | 3.27 | 3.59 | 3.87 | 3.85 | 4.00 | 3.87 | 4.26 | 4.28 | 4.42 | 4.52 | 5.77 | 5.89 | |
| Profit before tax | 18.25 | 20.50 | 25.18 | 14.74 | 9.65 | 13.86 | 13.71 | 9.89 | -11.62 | 10.74 | 25.34 | 8.81 | 5.89 | |
| Tax % | 24.55% | 23.02% | 26.01% | 24.69% | 23.42% | 24.96% | 29.39% | 24.67% | -14.63% | 13.04% | 25.57% | 23.84% | 25.47% | |
| Net Profit | 13.77 | 15.79 | 18.62 | 11.10 | 7.38 | 10.40 | 9.68 | 7.45 | -9.92 | 9.34 | 18.87 | 6.70 | 4.39 | |
| EPS in Rs | 2.86 | 3.28 | 3.86 | 2.30 | 1.53 | 2.16 | 2.01 | 1.54 | -2.06 | 1.94 | 3.91 | 1.39 | 0.91 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202641.83%Promoter
Promoters41.83%2.60
FIIs0.91%0.40
DIIs0.00%
Public57.26%2.20
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.76 | 4,52,251 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.16 | 1,78,374 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.53 | 1,23,980 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.42 | 1,19,700 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.47 | 1,16,119 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.81 | 1,14,316 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Kopran | ₹263.16 | 32.36 | 1,272 | 1.14% | 4 | +144.25% | 211 | +79.17% | 6.65% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,983 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Concall transcripts30
PPTNov 2026PPTAug 2026PPTMay 2026PPTJan 2026PPTNov 2025PPTNov 2025PPTJul 2025PPTMay 2025TranscriptMar 2025TranscriptFeb 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024PPTMay 2024TranscriptFeb 2024PPTFeb 2024PPTFeb 2024TranscriptNov 2023
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 19 NovVolume Movement Letter 13 Nov - Kopran says no undisclosed material event caused the recent volume surge.Clarification sought from Kopran Ltd 13 Nov - Exchange has sought clarification from Kopran Ltd on November 13, 2026, with reference to Movement in Volume.Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 13 Nov - Promoter Sarvamangal Mercantile bought 170,000 Kopran shares on Sept. 29, holding rose to 6.36%.Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Nov - Newspaper Publication of Financial Result Q2 of FY 2026-27.






